Clinical trial management company, BioClinica, has joined with advisory and consulting firm, Paragon Solutions, to conduct a study which will assess business challenges and trends facing clinical trial chain management.
AstraZeneca has become the latest drug firm to invest in Russian manufacturing capcity with the announcment of plans for a $150m facility in the country’s Kaluga region.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at INC Research, DPT, PharmaNet and CTI.
Lab Research's main Canadian lender has obtained an order appointing receivers under section 243 of the bankruptcy and insolvency act after the firm's US private equity suitor lost interest in a takeover.
GlaxoSmithKline (GSK) has confirmed that job cuts in its neurosciences group will affect less than 50 people, but half those cuts are coming from the company's US headquarters in North Carolina.
Non-clinical CRO CIT will distribute Stemina’s hES-based toxicity testing platform to pharmaceutical and cosmetics developers in Europe under an agreement announced late last week.
UK-based Endeavour Specialty Chemicals has launched a range of thioamide intermediates, citing growing evidence of their potential role in development of new cancer treatments.
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.
BioClinica grew service revenues in the fourth quarter and predicted the trend will continue in 2011 when it will “eliminate certain duplicate functions”.
Passwords used to protect personal health information in Canadian clinical trials are often too easy to crack, according to a report in the Journal of Medical Internet Research (JMIR).
US drugmaker Merck & Co has not found a buyer for an R&D lab operated by its MSD-Organon division may consider closing the facility, according to a number of media reports.
Pfizer’s Capsugel unit has bought an injection molding technology that, it believes, will expand its capsule filling business into new “high value segments.”
Takeda Pharmaceuticals has joined the growing list of pharma companies to forge strategic deals with contract research organisations (CRO) by signing new deals with Covance and Quintiles.
A global compulsory register of all contractors and subcontractors involved in each clinical trial should be created to increase transparency, according to a study.
Indian CRAMS firm Jubilant Life Sciences had an unhappy third quarter of fiscal 2011 with profits falling despite gains in generics and API manufacturing.
US-based Numira Biosciences has expanded its imaging and pre-clinical services portfolio after acquiring the efficacy pharmacology operating unit of Ricerca Biosciences.
Unilife saw its losses increase in the second quarter of fiscal 2011 on the lack of industrialisation revenue, higher R&D spending and the cost of its move to the US.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at PhRMA, BIO, Shire, Eli Lilly and DPT Laboratories.
German biotech firm Evotec has expanded its drug discovery and early development platform with the acquisition of Munich-based chemical proteomics specialists, Kinaxo.
QPS Holdings has acquired Taiwan’s Center of Toxicology and Preclinical Sciences (CTPS), continuing its expansion in the region’s rapidly expanding drug development sector.
Elan has entered into a development and manufacturing agreement with German pharmaceutical company, Boehringer Ingelheim, for antibody-based therapeutics.
The European Directorate for the Quality of Medicines & HealthCare (EQDM) has begun Phase 2 of its “track & track” anti-counterfeiting strategy and is seeking manufacturer participation.
Establishment of complex regulated preclinical studies in China is going to take a lot longer than expected, says CRL, with significant progress taking at least five years.